Introduction: Evidence of occupational exposure risks to novel anticancer agents is limited and yet to be formally evaluated from the Australian healthcare perspective. Methods: From March to September 2013 medical databases, organizational policies, drug monographs, and the World Wide Web were searched for evidence relating to occupational exposure to monoclonal antibodies, fusion proteins, gene therapies, and other unclassified novel anticancer agents. Results: Australian legislation, national and international guidelines, and drug company information excluded novel agents or provided inconsistent risk assessments and safe handling recommendations. Monoclonal antibody guidelines reported conflicting information and were often divergent with available evidence and pharmacologic rationale demonstrating minimal internalisation ability and occupational exposure risk. Despite similar physiochemical, pharmacologic, and internalisation properties to monoclonal antibodies, fusion proteins were included in only a minority of guidelines. Clinical directives for the safe handling of gene therapies and live vaccines were limited, where available focusing on prevention against exposure and cross-contamination. Although mechanistically different, novel small molecule agents (proteasome inhibitors), possess similar physiochemical and internalisation properties to traditional cytotoxic agents warranting cytotoxic classification and handling. Conclusion: Novel agents are rapidly emerging into clinical practice, and healthcare personnel have few resources to evaluate risk and provide safety recommendations. Novel agents possess differing physical, molecular and pharmacological profiles compared to traditional cytotoxic anticancer agents. Evaluation of occupational exposure risk should consider both toxicity and internalisation. Evidence-based guidance able to direct safe handling practices for novel anticancer agents across a variety of clinical settings is urgently required.
Introduction
Novel anticancer agents are in rapid development with many already in routine clinical use and others likely to emerge into clinical oncology and haematology practice in the near future. For the purposes of this review, novel anticancer agents were defined as agents used in the prevention, treatment or supportive care of cancer patients that are not alkylating agents, anti-metabolites, anti-microtubule agents, topoisomerase inhibitors, or cytotoxic antibiotics (anthracyclines). Relevant classes of anticancer agents therefore included monoclonal antibodies (MABs), fusion proteins (FPs), gene therapies, and other unclassified novel anticancer agents such as proteasome inhibitors and vaccines. These novel agents often possess different physiochemical, pharmaceutical, and pharmacologic properties compared to traditional agents. They often are not truly cytotoxic, do not clearly fulfil hazardous substance criteria nor have defined occupational exposure limits, 1,2 and do not meet chemical labelling classifications. 3, 4 This comprehensive literature review aimed to identify and evaluate available literature relating to occupational exposure risks and current practice standards for novel anticancer agents, focusing on the most commonly utilised and most widely available class of MABs.
Methods
A comprehensive literature review was undertaken between March and September 2013 to identify evidence relating to occupational exposure to MABs, FPs, gene therapies, and other unclassified novel anticancer agents. The literature was evaluated for current regulations and practice standards, and occupational exposure risks. Occupational exposure risk evaluation included assessment of toxicity (therapeutic and occupational exposure levels), internalisation potential (including animal studies and theoretical pharmacologic mechanisms), as well as manufacturing and operational considerations that may impact on occupational exposure or product integrity. Expecting a scarcity of data, no exclusion criteria or search limitations were applied. Following an initial broad search for all classes defined here as novel agents, the search was narrowed to MABs, the most commonly used and widely available class with the greatest impact for healthcare services.
Medical databases searched included Medline (OVID), Cumulative Index to Nursing and Allied Health Literature (CINAHL), Wiley Interscience, Embase, PubMed, and the Cochrane Library. Searches were conducted using both Medical Subject Heading (MeSH) terms and text words. The MeSH term MABs, was selected and initially exploded to include all subheadings. The search was then refined by combining the following text words: administration, exposure, guidelines, handling, metabolism, pharmacokinetics, pharmacokinetics, pharmacology, physiology, poisoning, or safety. The reference lists of relevant papers were also searched.
Organisational policy review included Australian government regulations, standards and codes of practice, Australian and international professional association guidelines (pharmacy, medical, and nursing) and publicly available institutional guidelines. Individual drug evaluations (product information (PI) and material safety data sheets (MSDS)) were undertaken for a subset of novel agents with the intention of describing a representative sample of novel anticancer molecules. Selection was based on agents which are commonly used in Australian oncology and haematology settings and which are reflective of the range of therapeutic drug classifications, parenteral administration routes, and preparation techniques. Drug evaluations were undertaken for aflibercept, alemtuzumab, Bacillus Calmette-Guerin (BCG), bevacizumab, bortezomib, brentuximab-vedotin, cetuximab, denosumab, ipilimumab, ofatumumab, panitumumab, rituximab, trastuzumab, and trastuzumab-emtansine. The World Wide Web (via Google) was searched for related unpublished material.
Results
Using the described methodology only a limited number of relevant scientific papers were identified, providing a low level of evidence from which to evaluate occupational health and safety risks (National Health and Medical Research Council (NHRMC) levels III-IV or non-gradable (animal and in vitro pharmacologic studies)). Risk evaluations of stated novel agents were undertaken considering cytotoxicity, organ toxicity at low doses, immunogenicity, teratogenicity, mutagenicity, carcinogenicity, molecular weight (MW), sterility and stability, and operational factors (required number of manufacturing steps and administration route), Table 1 . Evaluation of Australian legislation, professional organisation guidelines and practice standards, and independently published guidelines found exclusions, contradictions and variable practice recommendations for the safe handling of novel agents, Table 2 . Similar results were found within MAB specific guidelines, Table 3 .
Unclassified novel anticancer agents
Within this category of novel agents are diverse anticancer therapies (in action, morphology, and pharmacology) that are otherwise uncategorized, including proteasome inhibitors and live vaccines. Proteasome inhibitors are small molecule chemical entities developed from peptide aldehydes. 5 Bortezomib (United States Food and Drug Administration (FDA) and Therapeutic Goods Administration (TGA) approved) and carfilzomib (FDA approved) are currently approved for use in the treatment of multiple-myeloma with several other proteasome inhibitors under clinical investigation. 6, 7 Bortezomib, a dipeptide molecule (boronic acid analogue), was the first anti-cancer agent to target cancer cells via this mechanism and is licensed for both subcutaneous and intravenous administration. 8 Bortezomib exhibits direct cytotoxic activity by induction of proteolysis and distribution of signal cascades and homeostatic mechanisms. Classified as a cytotoxic agent, 9 bortezomib (and other proteasome inhibitors)
requires preparation and handling precautions as for other injectable cytotoxics. 10 BCG is live attenuated Mycobacterium bovis (tuberculosis) and is used as an immunostimulant in the treatment of bladder cancer. BCG has been in clinical use for over 30 years and 
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Journal of Oncology Pharmacy Practice 22 (1) works by producing localised inflammatory reactions resulting in elimination or reduction of superficial tumour lesions of the bladder. 11 Due to its biological nature, BCG is classified both as a hazardous substance and bio-hazardous material with all equipment, supplies, and receptacles in contact with BCG to be handled and disposed of as for biohazard material. 12 
Gene therapies
Currently no gene therapy agent is approved for clinical use anywhere in the world. However, more than 1800 gene therapy clinical trials in more than 30 different countries have been approved, completed or are ongoing with almost 65% within the oncology setting. 13 Gene therapy relies on the delivery of the therapeutic gene to the target site, achieved through the use of genetically modified organisms (GMOs) such as viruses. 14 In Australia, the Gene Technology Act 2000 regulates the use and handling of live and viable GMOs, with stated objective to protect people and the environment and to identify and manage risks associated with gene technology. 15 In Australia, human gene therapy (introducing a GMO into a human) requires licence from the Regulator. Australian pharmacy practice standards (Society of Hospital Pharmacists Australia (SHPA)) recommend that gene therapies be handled in dedicated negative pressure clean areas to prevent healthcare workers from yet undisclosed risks. 16 Practice standards from the International Society of Oncology Pharmacy Practitioners (ISOPP) stipulate that separate ventilation tools and cabinets be used for the preparation of gene therapies (and other biological products) so as to minimise cross-contamination. 17 According to the United Kingdom Health and Safety Executive (HSE), the majority of gene therapies in clinical research fall into the lowest occupational hazard categories (1 or 2) and that preparation (basic reconstitution or dilution) may occur in pharmacy manufacturing units, or in some circumstances at the bedside. 18 Class 1 agents do not require the use of biological safety cabinets for operator safety, rather the HSE recommend this as standard practice to safeguard product purity. HSE recommends actions to avoid cross-contamination including cabinet decontamination and disinfection and time lapse between cabinet use for different organisms.
Fusion proteins
Derived from fusion genes, which are themselves created by joining parts of two different genes, FPs differ from the chemical structure of traditional anticancer agents. They may occur naturally in the body by transfer of deoxyribonucleic acid (DNA) between chromosomes or may be created in the laboratory by the fusion of the crystalline fragment (Fc) of human Immunoglobulin G (IgG-1) (to provide sufficient biologic half-life for clinical application) with a natural human soluble receptor or ligand of a target molecule. 19 Occupational exposure risks associated with FPs are unclear and specific safe handling recommendations were largely lacking within broader hazardous substance guidelines and regulations, Table 2 . Where FPs were included, recommendations aligned with those for MABs based on structural similarities (large proteinaceous molecules). 20, 21 MSDS for FPs available in Australia (etanercept and abatacept; non-oncology indications) recommend exposure controls similar to those required for cytotoxic agents: safety glasses, gloves, lab coat or over garment, exhaust ventilation or containment, and respirator masks. 22, 23 FPs can be conjugated to other agents (antibodies or cytotoxics), 24 with handling recommendations based on the most hazardous component.
MABs
MABs have been absent in existing Australian occupational exposure and safe handling guidelines, Tables 2  and 3 , with the exception of a recently published position statement from the Cancer Pharmacists Group (CPG) of the Clinical Oncological Society of Australia (COSA). 21 At the time of this review, 14 MABs were approved by the FDA and 10 by the TGA, for use in the treatment of solid and haematological malignancies. 6, 7 Additionally, MABs with nononcology indications are used off-licence in cancer therapies and more than 100 new MABs are currently in development or undergoing regulatory review. 25 Derived from monoclonal cell lines, MABs comprise an antigen-binding fragment (Fab) and crystalline fragment (Fc) which facilitate engagement of tumour antigens and binding to receptor sites on an effector cell. 26 As protein rather than chemical entities, conventional toxicity tests are not necessarily appropriate or achievable. According to the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) guidelines (adopted by the Australian TGA, American FDA and the European Medicines Agency (EMA)), as pharmaceutical products derived from biotechnology, there is no requirement for MABs to be evaluated for either carcinogenicity or genotoxicity. 27 
MABs -external toxicity risk
No reports of MAB-induced healthcare personnel skin irritation or allergic reaction were identified. Contact allergies may be triggered by excipients such as tensides (Polysorbate (also known as Tween 20 & Tween 80)), which are found in numerous pharmaceutical formulations. 28 These excipients are utilised in MAB formulations to prevent surface adsorption, stabilise against protein aggregation, and retain biologic activity. 29 
MABs -internal toxicity risk
The toxicity profiles of evaluated MABs are summarised in Table 1 . Listed toxicities are reported from therapeutic administration with no reported toxicities from occupational exposure. Although no direct mechanism for cytotoxicity, a molecular study demonstrated that low concentrations (5 mg/kg) of investigational therapeutic epidermal growth factor (EGFR) specific MAB reduced tumour volume via antibody-dependent cellular cytotoxicity (ADCC) induction of EGFR signalling inhibition. 30 Additionally, MAB-polyethylene glycol (PEG) conjugate, Certolizumab-Pegol, has demonstrated cytotoxic activity by direct induction of death in non-apoptotic cells of transmembrane TNF-a expressing cells. 31 Several MAB-handling guidelines extrapolate toxicity profiles from therapeutic administration to the occupational exposure setting. [32] [33] [34] It has been suggested that the potential for occupational exposure of healthcare workers to unconjugated MABs and intact conjugates is minimal. 35 Bioavailability is the major determinant of internal exposure, 36 with the first and rate-limiting step being absorption: the uptake of the substance into the body systems. Possible routes of absorption following occupational exposure are direct contact (dermal or mucosal absorption), inhalation, or accidental ingestion or injection.
Dermal and inhalation routes are the most likely means of exposure in health care facilities. Quantitative structure-permeability relationships (QSPRs) indicate that molecular size (smaller molecular size associated with increasing skin permeation) and hydrophobicity (increasing hydrophobicity associated with increasing skin permeation) are the main determinants of transdermal penetration. 36 The molecular size of drugs for transdermal delivery (and of contact allergens) is typically less than 500 Da. 37 MABs are hydrophilic molecules, 38 with molecular size typically in excess of 140 KDa, Table 1 . Published guidelines and position statements agree that dermal absorption of MABs is unlikely, 20, 21, 39, 40 but still recommend wearing gloves, Table 3 . Whether gloves are recommended for occupational risk minimisation or for the protection of product integrity is not clearly stated.
Biophysical and functional evaluation demonstrated that MABs are able to withstand the constraints of physical agitation required for aerosolisation and retain structural integrity and activity. 41, 42 Inhalation of aerosolised MAB (cetuximab) in genetically modified (Babl/c nude) mice resulted in durable accumulation in the lungs with limited and slow passage into systemic circulation. 42 An unpublished animal study testing a variety of MAB inhalation and tracheal instillations in more than one animal species and with more than one MAB, found that MABs with MW between 120 and 200 KDa, expected absorption was less than 5%. 43 Published guidelines and position statements considered inhalation to be the most likely route of occupational exposure. 20, 21, 34 All evaluated guidelines that included safe handling recommendations recommended the use of protective masks during preparation and handling, Table 3 . The ability to generate liquid aerosols capable of reaching the alveoli during routine occupational conditions is debatable, 42 and one guideline recommended the use of protective masks for powered formulations only. 40 Vaginal mucosal drug delivery of MABs achieved high concentration in vaginal secretions (approximately 100 times lower in blood and other tissues) for up to 30 days after insertion of polymer vaginal rings (designed to provide continuous antibody delivery) in mice. 44 Porcine nasal mucosal MAB delivery (bevacizumab) achieved local but not systemic drug availability; 83% of original drug dose recovered within the nasal mucosa; 53% on the surface, 19% into and 11% through the mucosa. 45 Negligible systemic bioavailability was concluded in the absence of noticeable histological effects. Murine nasal mucosal MAB delivery (MAB MW 160 KDa) resulted in rapid increase in IgA and IgG antibody levels within lung lavage without transfer into bile and undetectable serum levels. 46 Ocular mucosal application of liposomeincorporated and free MAB (murine derived IgG1 anti CD4) to rat cornea (9 mg five times daily for 10 days) demonstrated significantly reduced rates of corneal transplant rejection (targeted activity). 47 Liposomal MAB, free MAB, and untreated rats experienced corneal rejection rates of 25%, 58%, and 63% respectively. Negligible systemic bioavailability was concluded in the absence of systemic depletion of targeted lymphocytes (flow cytometry analysis). Masks and protective eyewear afford protection against mucosal (nasal and ocular) absorption; recommendations varied within evaluated guidelines, Table 3 .
Pharmacological rationale dictates that oral ingestion of MABs will result in denaturation and inaction of the protein molecule by gastric acids and enzymes. [48] [49] [50] Animal 48 and human studies 49, 50 have demonstrated that MABs can survive gastric conditions and exert systemic activity. It has been demonstrated that the Fc portion of the antibody is not required for activity with similar effects observed with oral Fab fragments alone. 48 Fab fragments are more tolerant of acid environments compared to Fc fragments; Fc denaturation occurring at pH 3.5 vs. pH 2.0 for Fab. 51 
Manufacturing and operational considerations
Surface and airborne drug contamination (including within manufacturing units utilising robotic technology) is a recognised occupational hazard for cytotoxic anticancer agents. [52] [53] [54] [55] [56] [57] Similar studies reporting MAB contamination were not identified. The significance of MAB contamination (if present) is unknown. Cytotoxic contamination in Australian and Canadian hospital pharmacy departments has demonstrated a variety of surfaces within cytotoxic preparation areas including inside cabinets, on floors and on checking benches. [55] [56] [57] Gaseous drug (cyclophosphamide) has been detected in seven of 15 locations tested for airborne contaminants. 56 Personal protective equipment (PPE) has been tested for protection against surface, airborne, and direct contact with cytotoxic anticancer agents; similar studies for MABs were not identified. Protective gloves significantly reduce worker exposure associated with surface cytotoxic drug contamination. 53 Respiratory protection from atmospheric exposures and liquid spills are recommended within cytotoxic drug standards, 10, 17 and further defined within local (Australian and New Zealand) standards. 58, 59 Protective eyewear with side shields protects from splashes as the entire periphery of the goggle is in contact with the face, 60 and is recommended for handling of cytotoxic agents. 10, 17 Gowns with polyethylene or vinyl coating have proved to be superior to polypropylene homopolymer gowns which failed splash testing (allowing penetration of both water and non-water based cytotoxic agents). 61 Closed System Drug Transfer Devices (CSDTDs) offer protection to product and worker. Evaluation of five commercial brands found differing levels of contamination among the tested devices. 62 Only one product (PhaSeal Õ ) met the NIOSH and ISOPP definition of a CSDTD. 1, 17 The efficacy of PhaSeal Õ has been demonstrated in other Australian and international studies. [63] [64] [65] [66] [67] Some safe handling guidelines include consideration of drug complexity (dose calculation or reconstitution manipulation) when evaluating occupational exposure risk. 20, 21, 33 Lacking demonstrative studies, the implication is that complex or numerous manipulations may increase error and/or exposure risks to healthcare personnel (and contamination risks to the product). MABs vary in complexity from ready-to-use formulations to those requiring more than 20 manipulations, Table 1 . Interruptions during medication preparation in ward settings are frequent (more than five per hour) 68 and although the correlation with preparation error and exposure has not been evaluated, interruptions are associated with medication administration error. 69 Manufacturing and operational considerations impact on MAB integrity and must ensure the preservation of complex protein interactions including those with the solvent molecules, primary container, and other surfaces the MAB may come in contact with. [70] [71] [72] Not limited to MABs (or other novel agents) is the association of lesser operator technique with higher rates antimicrobial product contamination, [73] [74] [75] and conceivably (not demonstrated) higher risk of spillage and/or exposure. Microbial contamination risk is increased when vial-sharing outside of pharmacy controlled environments with demonstration of contamination, poor expiration date documentation and failure to discard (potential use of) expired stock. 76 Australian Pharmaceutical Benefits Scheme (PBS) funding is based on milligram of dose rather than vial, 77 which may encourage vial-sharing.
Discussion
Healthcare personnel are at risk of occupational exposure, including any staff exposed or potentially exposed to these agents or their metabolites, either through direct contact or exposure to contaminated body fluids such as blood, urine, or faeces. Licensing of agents for subcutaneous administration (bortezomib and denosumab, 78, 79 likely rituximab and trastuzumab, 80 and then other agents) is expected to lead to administration across a range of clinical and community settings outside of the hospital environment. It is therefore important that guidelines provide consistent risk assessments and unambiguous handling recommendations.
The processes involved in the preparation of many novel agents are complex, sensitive, or involve numerous and/or multifaceted manipulations (Table 1) but are only considered within three published guidelines. 20, 32, 34 Complex preparations infrequently performed or performed by inadequately trained personnel may present risks to healthcare personnel (occupational exposure) and the product (integrity and microbial contamination). Risks associated with vial-sharing on the ward 76 mean that institutions with large manufacturing units and an ability to vial-share (multiple patients treated with the same drug) may seek to reap financial benefits associated with PBS reimbursement by milligram rather than vial, 77 by vial-sharing within sterile manufacturing units regardless of occupational health and safety risks.
Studies evaluating the occupational exposure of novel agents (as for cytotoxic anticancer agents) are lacking and unlikely to be conducted. As such there is a reliance on animal studies, in vitro testing and pharmacologic principle. The divergent physical, molecular, and pharmacokinetic profiles of novel anticancer agents compared to cytotoxic agents and other chemical substances mean that current definitions for hazardous substances are not appropriate for the classification of these agents. Australian and international hazardous substance criteria include parameters (genotoxicity, carcinogenicity) not applicable, unable to be tested or not mandated to be tested for products derived from biotechnology. 1, 2, 27 Adding further difficulties in the classification of these agents is the evaluation of cytotoxicity and whether direct or indirect (immune-mediated) methods present equal risks to healthcare personnel. No MAB has direct cytotoxic activity nor is there a mechanism for the direct cytotoxic potential of MABs. However, they can exert cytotoxic effects via immunemodulation including ADCC and complement-dependent cytotoxicity (CDC). 30, 31 Beyond toxicity classification, the likelihood of systemic exposure in the occupational setting impacts on the ability of these agents to exert potentially hazardous effects. The most appropriate weighting for internalisation and toxicity risk is unclear. However, it must be considered that an agent with no means of internalisation, but which is reliant on internalisation to exert toxic effects, presents no (or negligible) occupational risk. Internalisation is impacted by the divergent physiochemical properties of novel agents. FPs have similar properties to MABs, both with proteinaceous morphology and MW significantly greater than novel small molecule chemical entities (proteasome inhibitors) and traditional anticancer agents. Etanercept (FPs) MW 130 KDa; 22 denosumab (MAB) MW 147 KDa; 79 Bortezomib (proteasome inhibitor) MW 384 Dalton; 78 and Cisplatin (alkylating agent) MW 300 Dalton. 81 Extrapolation of therapeutic toxicity profiles to the occupational exposure setting may be misleading considering available evidence relating to (lack of) potential systemic exposure routes for the large molecule proteinaceous agents, MABs and FPs. With no evidence of toxicity from topical contact and molecular properties limiting the likelihood of internalisation of MABs or FPs in the occupational exposure setting, these agents present with differing occupational exposure risks to cytotoxic agents and warrant different (lesser) safe handling requirements. Uncertainty is exemplified by the demonstration of MAB absorption (local and systemic) vial oral, mucosal (nasal, vaginal and ocular), and inhalation routes, despite unfavourable molecular and physicochemical properties (high MW and size and marked hydrophilia). Particularly noteworthy is the study demonstrating ocular absorption and biological activity (local not systemic) in a rat model at very low doses (<50 mcg/day), 47 which may reflect low doses associated with occupational exposure.
The United States National Institute for Occupational Safety and Health (NIOSH) describe disagreement between peer reviewers and stakeholders around the hazard evaluation of several MABs (bevacizumab, cetuximab, rituximab, and alemtuzumab). NIOSH ultimately declined the addition of bevacizumab, cetuximab, and rituximab (argued hazardous based on evidence of foetal toxicity and teratogenicity) and removed alemtuzumab (argued hazardous based on ability to cause marrow hypoplasia), due to low likelihood of substantial systemic exposure. 1 The 2012 list of antineoplastic and other hazardous drugs in healthcare settings will see brentuximab vedotin and ado-trastuzumab emtansine added in 2014. 82 MABs conjugated to radio-isotopes are not currently included because they are regulated by the United States Nuclear Regulatory Commission (NRC) (despite the availability of safe handling guidelines from manufacturers). 1, 83, 84 This conclusion, however, is based on low levels of evidence and uncertainties remain, which warrant a precautionary approach and consideration of interventions greater than for non-hazardous medications.
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